ProCE Banner Activity

BCT1902/IBCSG 61-20 Neo-N: Phase II Trial of Concurrent Nivolumab Plus Neoadjuvant Chemotherapy With and Without Lead-In Nivolumab in Stage I/II TNBC

Conference Coverage

Phase II Neo-N trial data suggest that a 12-week regimen of nivolumab plus neoadjuvant chemotherapy with or without a nivolumab lead-in, followed by surgery, leads to high pCR rates in patients with stage I/II triple negative breast cancer.

Released: December 10, 2023


Provided by

Provided by Clinical Care Options, LLC

ProCE Banner


Supported by educational grants from AstraZeneca, Daiichi Sankyo, Inc., Gilead Sciences, Inc., Lilly, Merck Sharp & Dohme LLC, and Seagen Inc.


Daiichi Sankyo, Inc.

Gilead Sciences, Inc.


Merck Sharp & Dohme, LLC

Seagen Inc.